FIELD: medicine.
SUBSTANCE: present invention relates to immunology. Disclosed is an antibody and its antigen-binding entity capable of specific binding to the human T-cell receptor beta-chain TRBV9 segment. Also disclosed are nucleic acids, expression vectors, a method for producing a host cell, a host cell, a method for producing an antibody or an antigen-binding fragment thereof and pharmaceutical compositions. Disclosed is a method for inhibiting the biological activity of the T-cell receptor, a method of treating a disease or disorder mediated by a human T-cell receptor, and using the antibody or pharmaceutical composition.
EFFECT: present invention can find further application in therapy of various conditions, particularly celiac disease, T-cell leukemia and T-cell lymphoma.
32 cl, 5 dwg, 3 tbl, 7 ex
Title | Year | Author | Number |
---|---|---|---|
MONOCLONAL ANTIBODIES WHICH SPECIFICALLY BIND TO THE BETA-CHAIN REGION OF THE TRBV-9 FAMILY OF THE HUMAN T-CELL RECEPTOR, AND METHODS FOR USE THEREOF | 2018 |
|
RU2711871C1 |
HUMANISED ANTI-BETA 9 CHAIN ANTIBODIES OF HUMAN TRBV9 TKP FAMILY, AND METHODS OF USING | 2018 |
|
RU2712251C1 |
CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND THEIR USE | 2018 |
|
RU2780020C2 |
MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS GITR | 2019 |
|
RU2734432C1 |
ANTI-CCR2 ANTIBODIES | 2009 |
|
RU2547595C2 |
MONOCLONAL PD-L1 ANTIBODY | 2017 |
|
RU2665790C1 |
ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 | 2018 |
|
RU2812915C2 |
MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
BISPECIFIC ANTIBODIES SPECIFIC TO PD1 AND TIM3 | 2016 |
|
RU2729371C1 |
ANTIBODIES TO HUMAN CSF-1R AND USE THEREOF | 2011 |
|
RU2617966C2 |
Authors
Dates
2019-07-12—Published
2017-12-25—Filed